pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
AMGEN · news · pharmadog
← back to AMGEN
News mentioning AMGEN
239
stories
11h
nChroma halves workforce, BioXcel lets execs go
biospace
19h
AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal
biospace
1d
8 companies hiring in North Carolina now
biospace
1d
AbbVie busts a move with Disco in $2.5B dance aimed at bispecific discovery
fiercebiotech
1d
5 acquisitions that forced Big Pharmas to co-parent
biospace
3d
Aclaris drops TSLP program from pipeline after flunking phase 2 eczema test
fiercebiotech
6d
Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
fiercebiotech
7d
Windward prices $175M IPO to advance China-licensed lung drugs
biopharma dive
7d
10 companies hiring in New Jersey
biospace
8d
Amgen builds Sjögren’s case with detailed phase 3 data ahead of Novartis showdown
fiercebiotech
9d
AbCellera becomes latest biotech to abandon dream of developing OX40 drug
fiercebiotech
9d
BioSpace 2027 Best Places to Work shines light on most admired employers
biospace
10d
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
biospace
10d
STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more
stat
10d
STAT+: Democrats begin asking: How far can we go on health care?
stat
10d
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
fiercebiotech
11d
STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype
stat
12d
STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries
stat
12d
STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
stat
12d
STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories
stat
13d
STAT+: Democrats’ midterm landslide spells relief for hospitals
stat
13d
STAT+: New tumor cases show common gene therapy tool can come with risk
stat
13d
Satellos' new Duchenne study endpoint; Amgen's Repatha cuts heart attack risk
endpoints
13d
STAT+: Amgen’s Repatha linked to fewer heart attacks
stat
13d
Sarepta’s new CEO confident in clinical execution as DMD competitors close in
biospace
14d
At ASH, drugmakers to showcase early data for three-pronged cancer therapies
biopharma dive
14d
Chutes & Ladders—Novo's longtime CFO to hang up gloves as Galderma exec steps in
fiercebiotech
14d
STAT+: Beyond statins, one drug lowered heart attack risk by 20%
stat
14d
AHA: Novartis’ Lp(a) drug shows zero benefit, casting shadow over Amgen and Lilly programs
fiercebiotech
14d
The top 12 companies hiring in biopharma now
biospace
← prev
page 1 of 8
next →